TAK-755

Phase 2Biologic

Takeda

TAK-755 is one of 85 biologic programs targeting Sickle Cell Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sickle Cell DiseaseActive, not recruiting

Thrombotic Thrombocytopenic PurpuraActive, not recruiting

Ischemic StrokeActive, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

Thrombotic Thrombocytopenic PurpuraPreclinical

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Repatha

Amgen

Preclinical

2 2

Proamatine

Takeda

Preclinical

2 3

TAK-755

Takeda

Phase 2

1 4

Levaquin

WWim Janssens

Preclinical

3 5

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 6

Tylenol

KKenvue Brands

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Thrombotic Thrombocytopenic Purpura

NCT04683003

Q4 2027

Phase 2Not yet recruiting

Ischemic Stroke

NCT07392450

Clinical

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura4 trials

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting· Takeda logo

Takeda·Phase 2·NCT05714969·33 enrolled

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting· Takeda logo

Takeda·Phase 3·NCT04683003·77 enrolled

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Approved for marketing· Takeda logo

Takeda··NCT05770219

Show 1 more trial

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed·BBaxalta now part of Shire·Phase 3·NCT03393975·52 enrolled

Ischemic stroke1 trial

A Study of TAK-755 in Adults With Acute Ischemic Stroke

Not yet recruiting· Takeda logo

Takeda·Phase 2·NCT07392450·222 enrolled

Sickle Cell Disease1 trial

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

Completed· Takeda logo

Takeda·Phase 1·NCT03997760·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for TAK-755. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-755 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-755. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-755

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Thrombotic Thrombocytopenic Purpura4 trials

Ischemic stroke1 trial

Sickle Cell Disease1 trial

References

Drug Info

Quick Facts

Related News